Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jozien Helleman

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Biomolecules|March 12, 2020
<i>TP53</i> Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian CancerSilvia R Vitale, Floris H Groenendijk, Ronald van Marion, et al.
Histopathology|June 20, 2020
Intraoperative assessment and reporting of radical prostatectomy specimens to guide nerve-sparing surgery in prostate cancer patients (NeuroSAFE)Margaretha A van der Slot, Michael A den Bakker, Sjoerd Klaver, et al.
International Journal of Cancer|November 16, 2005
Molecular profiling of platinum resistant ovarian cancerJozien Helleman, Maurice P H M Jansen, Paul N Span, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2016
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian CarcinomaBrandon Leonard, Gabriel J Starrett, Matthew J Maurer, et al.
European Urology Open Science|July 11, 2022
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 InitiativeSebastiaan Remmers, Jozien Helleman, Daan Nieboer, et al.
BJU International|May 10, 2022
NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcomeMargaretha A van der Slot, Michael A den Bakker, Tamara S C Tan, et al.
European Urology|August 25, 2024
Prostate Cancer Early Detection in the European Union and UKRenée C A Leenen, Lionne D F Venderbos, Jozien Helleman, et al.
European Urology Oncology|July 18, 2024
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical RegistryChris Bangma, Paul Doan, Lin Zhu, et al.
Journal of Personalized Medicine|July 27, 2024
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST SurveyKatharina Beyer, Renée C A Leenen, Lionne D F Venderbos, et al.
European Urology|May 24, 2024
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in EuropePieter Vynckier, Lieven Annemans, Sarah Raes, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Biomolecules|March 12, 2020
<i>TP53</i> Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian CancerSilvia R Vitale, Floris H Groenendijk, Ronald van Marion, et al.
Histopathology|June 20, 2020
Intraoperative assessment and reporting of radical prostatectomy specimens to guide nerve-sparing surgery in prostate cancer patients (NeuroSAFE)Margaretha A van der Slot, Michael A den Bakker, Sjoerd Klaver, et al.
International Journal of Cancer|November 16, 2005
Molecular profiling of platinum resistant ovarian cancerJozien Helleman, Maurice P H M Jansen, Paul N Span, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2016
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian CarcinomaBrandon Leonard, Gabriel J Starrett, Matthew J Maurer, et al.
European Urology Open Science|July 11, 2022
Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 InitiativeSebastiaan Remmers, Jozien Helleman, Daan Nieboer, et al.
BJU International|May 10, 2022
NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcomeMargaretha A van der Slot, Michael A den Bakker, Tamara S C Tan, et al.
European Urology|August 25, 2024
Prostate Cancer Early Detection in the European Union and UKRenée C A Leenen, Lionne D F Venderbos, Jozien Helleman, et al.
European Urology Oncology|July 18, 2024
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical RegistryChris Bangma, Paul Doan, Lin Zhu, et al.
Journal of Personalized Medicine|July 27, 2024
Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST SurveyKatharina Beyer, Renée C A Leenen, Lionne D F Venderbos, et al.
European Urology|May 24, 2024
Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in EuropePieter Vynckier, Lieven Annemans, Sarah Raes, et al.
Pageof 5